TriVentures

Cala Health, Inc. is a bioelectronic medicine company based in Burlingame, California, founded in 2013. It specializes in developing wearable neuromodulation therapies aimed at treating chronic diseases. The company's flagship product, Cala Trio, is a non-invasive prescription therapy designed to provide transient relief from hand tremors in adults with essential tremor. By integrating advancements in neuroscience and technology, Cala Health focuses on delivering individualized peripheral nerve stimulation. In addition to its work on essential tremor, the company is also developing therapies for other neurological conditions, including Parkinson's disease, as well as applications in psychiatry, cardiology, and autoimmune disorders.

TailorMed is a health IT company that works with providers, pharmacies and manufacturers to reduce patient financial toxicity and create efficiencies across the patient treatment lifecycle. Our end-to-end platform applies algorithms and automations to make the co-pay assistance and free drug order processes seamless and leverages our deep data set to create actionable insights.

Grin operates a digital orthodontic platform that facilitates teeth straightening for a diverse range of patients through connections with local orthodontists. Founded by Dr. Adam Schulhof, Pamela Oren-Artzi, and Alon Lipnik in 2019, the company is based in New York and Austin. Grin's technology allows for quality orthodontic care via smart devices, enhancing accessibility and cost-effectiveness. The platform features patent-pending tools, including the Grin App and Grin Scope, which enable remote monitoring and virtual check-ins, thereby allowing orthodontists to oversee treatment progress without requiring frequent in-office visits. This approach not only improves patient convenience but also helps practitioners manage their time more efficiently while maintaining high standards of care. Grin aims to ensure that every patient receives the appropriate treatment for achieving an exceptional smile.

Monogoto is a provider of a cloud-based cellular network that facilitates global cellular connectivity and secure private LTE networks. Its API-driven Infrastructure-as-a-Service is designed to integrate seamlessly with existing enterprise IT systems, offering hundreds of ready-to-use APIs for various applications, including IoT, Private LTE, and 5G. Monogoto's services feature full auditing of network events, anomaly detection, and automated alerts, allowing businesses to monitor their connectivity effectively. The solution operates on an "as-a-Service" model, enabling customers to access advanced cellular value-added services without upfront capital expenditures. Monogoto's network provides public connectivity in 180 countries and supports compliance with regulations through an on-premise local breakout topology for private LTE and 5G networks, ensuring users can maintain optimal and continuous connectivity.

Brightside Health, Inc. is a telemedicine platform that specializes in providing evidence-based treatments for anxiety and depression. Founded in 2017 and based in San Francisco, California, the company has developed a mobile application that offers personalized mental health care through video visits, messaging, and medication delivery. Its platform enables users to evaluate their mental health, access treatment and support, and communicate with healthcare providers for consultations and ongoing care. Brightside Health utilizes a care model that combines precision psychiatry with continuous monitoring, ensuring members receive effective treatment tailored to their needs. The company’s mission is to help individuals manage their mental health, leading to healthier and more productive lives.

BioProtect Ltd. is an international medical device startup focused on developing and commercializing biodegradable balloon spacers designed to protect normal tissue during cancer radiation therapy. The company's flagship product, the ProSpace balloon spacer, has demonstrated superior efficacy and safety in safeguarding the rectum during radiation treatment for prostate cancer. This innovative technology significantly reduces the risk of serious and chronic side effects associated with radiation, while enhancing tumor control. Founded in 2004 and headquartered in Israel, BioProtect also operates subsidiaries in Germany and the United States, aiming to address unmet clinical needs in the growing radiotherapy spacers market with its platform of biodegradable implantable balloons.

FeelBetter is a healthcare optimization platform founded in 2018 and based in Tel Aviv, Israel. The company focuses on value-based models to identify at-risk patients and recommend appropriate interventions. Its platform enhances both financial and clinical outcomes by analyzing individual health journeys, allowing healthcare organizations to diagnose potential issues before they escalate. By delivering personalized data and actionable insights, FeelBetter aims to improve the quality of care and overall business results for healthcare providers.

Flow is the Next-Gen Specialty Brokerage for commercial insurance. We blend human expertise with cutting-edge technology to deliver access to top markets.

FEMSelect Inc. specializes in designing and developing surgical systems and devices for pelvic floor ligament fixation, focusing on women's health. The company is known for its innovative EnPlace system, a minimally invasive and mesh-free solution for treating pelvic organ prolapse (POP). This patented technology allows for precise guidance and deployment of an anchor unit that stabilizes the pelvic floor ligament through a vaginal approach, significantly enhancing patient recovery and comfort. The procedure typically takes about 30 minutes and does not require overnight hospital stays or result in visible scarring. Founded in 2012, FEMSelect operates from its headquarters in Newark, Delaware.

Future Family, Inc. is a subscription-based fertility company founded in 2016 and headquartered in San Francisco, California. It provides comprehensive healthcare solutions for individuals and couples navigating fertility challenges, offering plans that cover all associated costs. The company's services include personalized fertility planning, clinic matching, and a dedicated nurse concierge, ensuring 24/7 access to a care team. Future Family specializes in on-demand medical support for procedures such as in vitro fertilization (IVF) and egg freezing, and it features a digital health platform for managing fertility care. By combining financial assistance with expert guidance, Future Family aims to deliver a stress-free fertility experience for its clients.

PayGround, Inc. specializes in developing billing and payment software solutions tailored for the healthcare industry. Founded in 2018 and headquartered in Chandler, Arizona, the company offers a cloud-based financial platform that allows healthcare providers to manage patient accounts efficiently. This includes creating and sending invoices, tracking payments, and accessing billing analytics. Patients benefit from the platform by having the ability to view and pay their bills quickly, using various methods such as email, text, or U.S. Mail. By streamlining the payment process, PayGround assists healthcare businesses in reducing costs and simplifying the management of multiple accounts, ultimately enhancing the billing experience for both providers and patients.

Brightside Health, Inc. is a telemedicine platform that specializes in providing evidence-based treatments for anxiety and depression. Founded in 2017 and based in San Francisco, California, the company has developed a mobile application that offers personalized mental health care through video visits, messaging, and medication delivery. Its platform enables users to evaluate their mental health, access treatment and support, and communicate with healthcare providers for consultations and ongoing care. Brightside Health utilizes a care model that combines precision psychiatry with continuous monitoring, ensuring members receive effective treatment tailored to their needs. The company’s mission is to help individuals manage their mental health, leading to healthier and more productive lives.

Day Zero Diagnostics Inc. is an infectious disease diagnostics company focused on developing rapid, sequencing-based diagnostics that identify bacterial pathogens and their antibiotic resistance profiles. The company employs advanced technologies such as Blood2Bac, which enhances bacterial DNA recovery from clinical samples, and BacDetect, designed for the swift detection of bacterial DNA. Its Keynome ID algorithm classifies bacterial species, while Keynome g-AST utilizes machine learning for genomic antibiotic susceptibility testing. Additionally, Day Zero maintains MicrohmDB, a comprehensive database that integrates whole genome sequencing data with resistance and susceptibility profiles of clinically relevant pathogens. Founded in 2016 and based in Boston, Massachusetts, Day Zero aims to transform infectious disease diagnostics by providing complete diagnoses—including species identification and antibiotic resistance—within hours, significantly improving treatment outcomes and reducing costs associated with prolonged diagnostic processes.

V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

Monogoto is a provider of a cloud-based cellular network that facilitates global cellular connectivity and secure private LTE networks. Its API-driven Infrastructure-as-a-Service is designed to integrate seamlessly with existing enterprise IT systems, offering hundreds of ready-to-use APIs for various applications, including IoT, Private LTE, and 5G. Monogoto's services feature full auditing of network events, anomaly detection, and automated alerts, allowing businesses to monitor their connectivity effectively. The solution operates on an "as-a-Service" model, enabling customers to access advanced cellular value-added services without upfront capital expenditures. Monogoto's network provides public connectivity in 180 countries and supports compliance with regulations through an on-premise local breakout topology for private LTE and 5G networks, ensuring users can maintain optimal and continuous connectivity.

TailorMed is a health IT company that works with providers, pharmacies and manufacturers to reduce patient financial toxicity and create efficiencies across the patient treatment lifecycle. Our end-to-end platform applies algorithms and automations to make the co-pay assistance and free drug order processes seamless and leverages our deep data set to create actionable insights.

Brightside Health, Inc. is a telemedicine platform that specializes in providing evidence-based treatments for anxiety and depression. Founded in 2017 and based in San Francisco, California, the company has developed a mobile application that offers personalized mental health care through video visits, messaging, and medication delivery. Its platform enables users to evaluate their mental health, access treatment and support, and communicate with healthcare providers for consultations and ongoing care. Brightside Health utilizes a care model that combines precision psychiatry with continuous monitoring, ensuring members receive effective treatment tailored to their needs. The company’s mission is to help individuals manage their mental health, leading to healthier and more productive lives.

Grin operates a digital orthodontic platform that facilitates teeth straightening for a diverse range of patients through connections with local orthodontists. Founded by Dr. Adam Schulhof, Pamela Oren-Artzi, and Alon Lipnik in 2019, the company is based in New York and Austin. Grin's technology allows for quality orthodontic care via smart devices, enhancing accessibility and cost-effectiveness. The platform features patent-pending tools, including the Grin App and Grin Scope, which enable remote monitoring and virtual check-ins, thereby allowing orthodontists to oversee treatment progress without requiring frequent in-office visits. This approach not only improves patient convenience but also helps practitioners manage their time more efficiently while maintaining high standards of care. Grin aims to ensure that every patient receives the appropriate treatment for achieving an exceptional smile.

EyeYon Medical Ltd. is an Israeli company specializing in the development of medical devices for the treatment of corneal edema. Founded by a team of experienced professionals in ophthalmology and business, the company is based in Jerusalem and operates within the Van Leer Technology Incubator. Its key products include Hyper-CL, a hyperosmotic contact lens that utilizes osmosis to extract fluids from corneal edema, thereby improving vision and alleviating pain. Additionally, EyeYon Medical offers DSPEK, an artificial endothelial layer designed to replace damaged endothelial tissue, which is crucial in cases of corneal edema. The company's innovative solutions are non-invasive, comfortable, and facilitate effective eye care for patients dealing with both acute and chronic ocular conditions.

BurnAlong, Inc. is a fitness and wellness platform that provides personalized online classes and social motivation to help individuals achieve their health goals. Founded in 2016 and based in Pikesville, Maryland, the company connects users with fitness instructors through video feeds, allowing them to work out together regardless of location. The platform serves a diverse clientele, including corporate employers, municipalities, insurers, brokers, individuals, and senior citizens. By leveraging machine learning, BurnAlong tailors class recommendations to suit various preferences, ranging from high-intensity workouts to meditation. This approach not only enhances individual wellness but also helps companies foster strong workplace cultures, enhancing employee retention and attraction.

PayGround, Inc. specializes in developing billing and payment software solutions tailored for the healthcare industry. Founded in 2018 and headquartered in Chandler, Arizona, the company offers a cloud-based financial platform that allows healthcare providers to manage patient accounts efficiently. This includes creating and sending invoices, tracking payments, and accessing billing analytics. Patients benefit from the platform by having the ability to view and pay their bills quickly, using various methods such as email, text, or U.S. Mail. By streamlining the payment process, PayGround assists healthcare businesses in reducing costs and simplifying the management of multiple accounts, ultimately enhancing the billing experience for both providers and patients.

Medisafe is a digital patient engagement platform focused on improving medication adherence and management. By utilizing a data-driven approach, the platform personalizes patient engagement, helping users navigate the complexities of their medication schedules. Medisafe addresses common challenges associated with non-adherence by providing features that send alerts to users and their caretakers, ensuring timely medication intake. With nearly 5 million registered users and over 2 billion recorded medication doses, the app has demonstrated its effectiveness in improving adherence by up to 20%, as evidenced by various studies. The platform engages both patients and healthcare partners, offering insights into behavior patterns that enhance the patient experience. Medisafe has received multiple accolades for its innovation in healthcare, including recognition from Gartner and Fast Company, and boasts high user satisfaction ratings, making it a leading solution in medication management.

Genoox, Ltd. is a company that develops a cloud-based platform for managing and analyzing genomic data. Founded in 2014, the company aims to create a comprehensive network of real-world genomic and clinical data to enhance genetic diagnostics and personalized treatments. The platform connects clinicians, genetic counselors, and healthcare organizations, allowing them to share insights and make significant discoveries using advanced genomic tools and applications. By leveraging artificial intelligence and machine learning, Genoox's platform translates complex genetic data into actionable clinical information, helping healthcare providers to analyze rare genetic mutations and improve patient outcomes with increased accuracy and efficiency. The company is headquartered in Israel and serves over 1,700 health organizations across 44 markets worldwide.

V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

BioProtect Ltd. is an international medical device startup focused on developing and commercializing biodegradable balloon spacers designed to protect normal tissue during cancer radiation therapy. The company's flagship product, the ProSpace balloon spacer, has demonstrated superior efficacy and safety in safeguarding the rectum during radiation treatment for prostate cancer. This innovative technology significantly reduces the risk of serious and chronic side effects associated with radiation, while enhancing tumor control. Founded in 2004 and headquartered in Israel, BioProtect also operates subsidiaries in Germany and the United States, aiming to address unmet clinical needs in the growing radiotherapy spacers market with its platform of biodegradable implantable balloons.

TuneFork develops audio personalization technology software aimed at enhancing the hearing experience for users. The software enables individuals to conduct a straightforward hearing test that generates a unique Audio Profile based on their specific hearing characteristics. This profile is used to adjust sound output, ensuring that users receive a tailored audio experience that compensates for their hearing capabilities. The technology can be integrated into various devices, including smartphones, smart TVs, and other IoT devices, optimizing audio across different content types such as phone calls, music, and video. With a focus on accuracy, TuneFork's self-test is clinically validated and provides reliable results, setting a high standard for audio personalization. The company's software-only solution, supported by two patent applications, addresses the diverse needs of users, from those with hearing impairments to those seeking enhanced audio quality.

Latica, formerly known as Lynx.MD, is a healthcare data company established in 2019, focused on transforming medical research and innovation. The company offers a secure platform that facilitates the sharing of clinical and operational data among life sciences organizations, healthcare providers, and researchers. By leveraging advanced technologies such as artificial intelligence and data analytics, Latica aims to unlock the potential of previously siloed healthcare data, fostering collaboration and driving significant advancements in patient care. The platform prioritizes security and patient privacy, enabling compliant partnerships for clinical and operational research. Through its innovative approach, Latica delivers actionable insights that enhance outcomes for patients and contribute to the evolution of healthcare practices.

TailorMed is a health IT company that works with providers, pharmacies and manufacturers to reduce patient financial toxicity and create efficiencies across the patient treatment lifecycle. Our end-to-end platform applies algorithms and automations to make the co-pay assistance and free drug order processes seamless and leverages our deep data set to create actionable insights.

Cala Health, Inc. is a bioelectronic medicine company based in Burlingame, California, founded in 2013. It specializes in developing wearable neuromodulation therapies aimed at treating chronic diseases. The company's flagship product, Cala Trio, is a non-invasive prescription therapy designed to provide transient relief from hand tremors in adults with essential tremor. By integrating advancements in neuroscience and technology, Cala Health focuses on delivering individualized peripheral nerve stimulation. In addition to its work on essential tremor, the company is also developing therapies for other neurological conditions, including Parkinson's disease, as well as applications in psychiatry, cardiology, and autoimmune disorders.

TailorMed is a health IT company that works with providers, pharmacies and manufacturers to reduce patient financial toxicity and create efficiencies across the patient treatment lifecycle. Our end-to-end platform applies algorithms and automations to make the co-pay assistance and free drug order processes seamless and leverages our deep data set to create actionable insights.

Day Zero Diagnostics Inc. is an infectious disease diagnostics company focused on developing rapid, sequencing-based diagnostics that identify bacterial pathogens and their antibiotic resistance profiles. The company employs advanced technologies such as Blood2Bac, which enhances bacterial DNA recovery from clinical samples, and BacDetect, designed for the swift detection of bacterial DNA. Its Keynome ID algorithm classifies bacterial species, while Keynome g-AST utilizes machine learning for genomic antibiotic susceptibility testing. Additionally, Day Zero maintains MicrohmDB, a comprehensive database that integrates whole genome sequencing data with resistance and susceptibility profiles of clinically relevant pathogens. Founded in 2016 and based in Boston, Massachusetts, Day Zero aims to transform infectious disease diagnostics by providing complete diagnoses—including species identification and antibiotic resistance—within hours, significantly improving treatment outcomes and reducing costs associated with prolonged diagnostic processes.

Latica, formerly known as Lynx.MD, is a healthcare data company established in 2019, focused on transforming medical research and innovation. The company offers a secure platform that facilitates the sharing of clinical and operational data among life sciences organizations, healthcare providers, and researchers. By leveraging advanced technologies such as artificial intelligence and data analytics, Latica aims to unlock the potential of previously siloed healthcare data, fostering collaboration and driving significant advancements in patient care. The platform prioritizes security and patient privacy, enabling compliant partnerships for clinical and operational research. Through its innovative approach, Latica delivers actionable insights that enhance outcomes for patients and contribute to the evolution of healthcare practices.

Genoox, Ltd. is a company that develops a cloud-based platform for managing and analyzing genomic data. Founded in 2014, the company aims to create a comprehensive network of real-world genomic and clinical data to enhance genetic diagnostics and personalized treatments. The platform connects clinicians, genetic counselors, and healthcare organizations, allowing them to share insights and make significant discoveries using advanced genomic tools and applications. By leveraging artificial intelligence and machine learning, Genoox's platform translates complex genetic data into actionable clinical information, helping healthcare providers to analyze rare genetic mutations and improve patient outcomes with increased accuracy and efficiency. The company is headquartered in Israel and serves over 1,700 health organizations across 44 markets worldwide.

Full-service website design and development for local service-based companies.

V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

Vi Labs is a prominent provider of enterprise AI solutions specifically tailored for the health sector. The company focuses on assisting large health organizations in enhancing member health outcomes while optimizing financial returns. By utilizing a robust technology stack and comprehensive household-level data, Vi Labs employs predictive and personalized engagement strategies. These approaches aim to reduce costs associated with member acquisition and increase the lifetime value of members. Ultimately, Vi Labs' solutions empower health enterprises to improve health outcomes for their members while maximizing overall income.

CathWorks Ltd. is a medical technology company that specializes in enhancing percutaneous coronary intervention (PCI) therapy decisions through its advanced computational science platform. Founded in 2013 and headquartered in Kfar-Saba, Israel, with an additional office in the United States, the company has developed the CathWorks FFRangio, a non-invasive device that provides objective, multi-vessel physiologic measurements. This tool transforms coronary angiography from a subjective visual assessment into an objective decision-making framework based on fractional flow reserve (FFR) metrics. By utilizing sophisticated algorithms to process visual information, CathWorks aims to improve the efficiency of cath lab operations and support healthcare providers in making data-driven clinical decisions.

Colospan Ltd is a clinical-stage medical device company based in Kfar Saba, Israel, that specializes in developing innovative solutions for colorectal surgeries. Founded in 2010, the company has created proprietary technology aimed at preventing anastomotic leaks and minimizing the need for diverting colonic stomas. Its lead product is a single-use, temporary intraluminal bypass device designed to reduce contact between fecal matter and the anastomotic site after procedures such as colectomy, which is often necessary in cases of severe intestinal inflammatory diseases and bowel or rectal cancer. By addressing the risk of leakage that can lead to prolonged hospitalization or additional surgeries, Colospan's devices aim to improve patient outcomes and facilitate a smoother recovery process while mitigating post-operative complications.

Colospan Ltd is a clinical-stage medical device company based in Kfar Saba, Israel, that specializes in developing innovative solutions for colorectal surgeries. Founded in 2010, the company has created proprietary technology aimed at preventing anastomotic leaks and minimizing the need for diverting colonic stomas. Its lead product is a single-use, temporary intraluminal bypass device designed to reduce contact between fecal matter and the anastomotic site after procedures such as colectomy, which is often necessary in cases of severe intestinal inflammatory diseases and bowel or rectal cancer. By addressing the risk of leakage that can lead to prolonged hospitalization or additional surgeries, Colospan's devices aim to improve patient outcomes and facilitate a smoother recovery process while mitigating post-operative complications.

ZingBox Inc. specializes in enterprise Internet of Things (IoT) security solutions, focusing on the discovery and protection of connected devices. Established in 2014 and headquartered in Mountain View, California, the company primarily serves the healthcare and manufacturing sectors. ZingBox offers a real-time security platform that detects anomalous behavior and enforces policies to safeguard against cyber threats and insider risks. This cloud-based solution maps out the entire network of connected devices, allowing clients to establish a baseline of normal behavior and identify potential risks effectively. ZingBox has formed a strategic partnership with First Health Advisory Solutions and operates as a subsidiary of Palo Alto Networks, Inc.

EyeYon Medical Ltd. is an Israeli company specializing in the development of medical devices for the treatment of corneal edema. Founded by a team of experienced professionals in ophthalmology and business, the company is based in Jerusalem and operates within the Van Leer Technology Incubator. Its key products include Hyper-CL, a hyperosmotic contact lens that utilizes osmosis to extract fluids from corneal edema, thereby improving vision and alleviating pain. Additionally, EyeYon Medical offers DSPEK, an artificial endothelial layer designed to replace damaged endothelial tissue, which is crucial in cases of corneal edema. The company's innovative solutions are non-invasive, comfortable, and facilitate effective eye care for patients dealing with both acute and chronic ocular conditions.

Medisafe is a digital patient engagement platform focused on improving medication adherence and management. By utilizing a data-driven approach, the platform personalizes patient engagement, helping users navigate the complexities of their medication schedules. Medisafe addresses common challenges associated with non-adherence by providing features that send alerts to users and their caretakers, ensuring timely medication intake. With nearly 5 million registered users and over 2 billion recorded medication doses, the app has demonstrated its effectiveness in improving adherence by up to 20%, as evidenced by various studies. The platform engages both patients and healthcare partners, offering insights into behavior patterns that enhance the patient experience. Medisafe has received multiple accolades for its innovation in healthcare, including recognition from Gartner and Fast Company, and boasts high user satisfaction ratings, making it a leading solution in medication management.

OrthoSpace Ltd. is an Israeli company specializing in the development and commercialization of biodegradable balloon systems designed to treat rotator cuff syndrome. Founded in 2009 and based in Caesarea, the company focuses on creating innovative solutions that aim to alleviate pain and enhance patients' range of motion while preserving their bone and joint structures. Its flagship product, InSpace™, has received the CE mark and is marketed in Europe, providing a non-invasive option for patients suffering from rotator cuff injuries. The balloon system mimics the function of the original bursa, acting as a spacer between the acromion and the humeral head to facilitate smooth movement and reduce friction during shoulder motion. As of 2019, OrthoSpace operates as a subsidiary of Stryker Corporation.

Vi Labs is a prominent provider of enterprise AI solutions specifically tailored for the health sector. The company focuses on assisting large health organizations in enhancing member health outcomes while optimizing financial returns. By utilizing a robust technology stack and comprehensive household-level data, Vi Labs employs predictive and personalized engagement strategies. These approaches aim to reduce costs associated with member acquisition and increase the lifetime value of members. Ultimately, Vi Labs' solutions empower health enterprises to improve health outcomes for their members while maximizing overall income.

V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

6over6 is a digital healthcare company that has created a platform allowing users to conduct their own eye vision tests using their smartphones. The platform integrates essential optometric tools to accurately measure the refractive error of the eye, facilitating the prescription of eyeglasses and contact lenses. By utilizing software to retrieve optical parameters from existing eyewear, 6over6 aims to make vision care more accessible. Their product, GlassesOn, is registered as a Class 1 Exempt Medical Device with the FDA. However, it is important to note that GlassesOn does not offer medical advice and is not a substitute for a comprehensive eye health examination.

MST Medical Surgery Technologies Ltd. develops innovative image analysis software aimed at enhancing surgical procedures in the healthcare sector. Founded in 2005 by entrepreneurs Ziv Tamir and Moti Sholev, the company is headquartered in Tel Aviv, Israel, with an additional office in Apollo Beach, Florida. MST's flagship product, AutoLap, is a robotic image-guided laparoscope positioning system that utilizes advanced image analysis technology to provide surgeons with real-time control during operations, ensuring an optimal field of view. Additionally, the company offers Surgical Training Analytics (STA), a tool designed to capture and analyze images from actual surgeries performed by trainee surgeons. By leveraging artificial intelligence, machine learning, and data analytics, MST aims to empower and automate the surgical environment, thereby improving outcomes for surgeons, healthcare providers, and patients alike.

OrthoSpace Ltd. is an Israeli company specializing in the development and commercialization of biodegradable balloon systems designed to treat rotator cuff syndrome. Founded in 2009 and based in Caesarea, the company focuses on creating innovative solutions that aim to alleviate pain and enhance patients' range of motion while preserving their bone and joint structures. Its flagship product, InSpace™, has received the CE mark and is marketed in Europe, providing a non-invasive option for patients suffering from rotator cuff injuries. The balloon system mimics the function of the original bursa, acting as a spacer between the acromion and the humeral head to facilitate smooth movement and reduce friction during shoulder motion. As of 2019, OrthoSpace operates as a subsidiary of Stryker Corporation.

Angioslide, Ltd. is a medical device company established in 2005 and headquartered in Natanya, Israel, with additional subsidiaries in Karlsruhe, Germany, and Edina, Minnesota. The company specializes in developing innovative angioplasty products, notably the Angioslide eXtra balloon catheter, which serves both as a stand-alone balloon for angioplasty and as a device for debris removal. Its proprietary Embolic Capture Angioplasty™ technology allows physicians to capture and eliminate embolic particles, chronic thrombus, and atherosclerotic plaque debris during angioplasty procedures. Angioslide focuses on addressing the needs of various markets, including peripheral artery, lower limb artery, carotid, and coronary artery diseases.

EyeYon Medical Ltd. is an Israeli company specializing in the development of medical devices for the treatment of corneal edema. Founded by a team of experienced professionals in ophthalmology and business, the company is based in Jerusalem and operates within the Van Leer Technology Incubator. Its key products include Hyper-CL, a hyperosmotic contact lens that utilizes osmosis to extract fluids from corneal edema, thereby improving vision and alleviating pain. Additionally, EyeYon Medical offers DSPEK, an artificial endothelial layer designed to replace damaged endothelial tissue, which is crucial in cases of corneal edema. The company's innovative solutions are non-invasive, comfortable, and facilitate effective eye care for patients dealing with both acute and chronic ocular conditions.

Medisafe is a digital patient engagement platform focused on improving medication adherence and management. By utilizing a data-driven approach, the platform personalizes patient engagement, helping users navigate the complexities of their medication schedules. Medisafe addresses common challenges associated with non-adherence by providing features that send alerts to users and their caretakers, ensuring timely medication intake. With nearly 5 million registered users and over 2 billion recorded medication doses, the app has demonstrated its effectiveness in improving adherence by up to 20%, as evidenced by various studies. The platform engages both patients and healthcare partners, offering insights into behavior patterns that enhance the patient experience. Medisafe has received multiple accolades for its innovation in healthcare, including recognition from Gartner and Fast Company, and boasts high user satisfaction ratings, making it a leading solution in medication management.

BioGaming offers an innovative virtual reality platform aimed at enhancing rehabilitation outcomes for patients undergoing physiotherapy. The company utilizes home-based gaming consoles and advanced 3D sensing technologies to monitor patient performance. By incorporating clinically developed exercise routines, BioGaming creates an engaging virtual environment where rehabilitation exercises are gamified, making them more enjoyable for users. The platform employs motion analysis systems and machine learning algorithms to generate detailed quantitative and qualitative reports on patient progress, allowing physical therapists to remotely prescribe and adjust exercise programs effectively. This dual approach benefits both patients, who experience a more engaging rehabilitation process, and therapists, who gain valuable insights into their patients' performance.

Cardiva Medical, Inc. is a medical device company that specializes in vascular access management products designed to facilitate the body's healing process after catheterization procedures. The company offers several innovative products, including the VASCADE VCS, an extravascular and bioabsorbable femoral access closure system that promotes rapid hemostasis while reducing complications. Additionally, Cardiva Medical provides the Cardiva CATALYST, a manual compression assistance device that enhances coagulation for patients requiring temporary hemostasis. Another key product is the VASCADE MVP, which is used for multi-site venous closure during electrophysiology procedures, such as cardiac ablation. Founded in 2002 and headquartered in Santa Clara, California, Cardiva Medical serves physicians and cardiac centers throughout the United States, focusing on transforming vascular closure practices to improve patient outcomes.

Apica Cardiovascular is a pre-revenue medical device company focused on a novel technology for accessing and closing the heart's apex and the peripheral vascular system. This technology facilitates the delivery of large therapeutic devices, such as transcatheter heart valves and devices used in aortic aneurysm repair and left ventricular assist device implantation, through minimally invasive surgical or percutaneous approaches. By standardizing access and closure techniques, the technology aims to minimize blood loss during procedures on a beating heart. Having successfully demonstrated its initial concept in animal and cadaver models, Apica Cardiovascular is now preparing to advance to initial clinical trials.

Medisafe is a digital patient engagement platform focused on improving medication adherence and management. By utilizing a data-driven approach, the platform personalizes patient engagement, helping users navigate the complexities of their medication schedules. Medisafe addresses common challenges associated with non-adherence by providing features that send alerts to users and their caretakers, ensuring timely medication intake. With nearly 5 million registered users and over 2 billion recorded medication doses, the app has demonstrated its effectiveness in improving adherence by up to 20%, as evidenced by various studies. The platform engages both patients and healthcare partners, offering insights into behavior patterns that enhance the patient experience. Medisafe has received multiple accolades for its innovation in healthcare, including recognition from Gartner and Fast Company, and boasts high user satisfaction ratings, making it a leading solution in medication management.

Angioslide, Ltd. is a medical device company established in 2005 and headquartered in Natanya, Israel, with additional subsidiaries in Karlsruhe, Germany, and Edina, Minnesota. The company specializes in developing innovative angioplasty products, notably the Angioslide eXtra balloon catheter, which serves both as a stand-alone balloon for angioplasty and as a device for debris removal. Its proprietary Embolic Capture Angioplasty™ technology allows physicians to capture and eliminate embolic particles, chronic thrombus, and atherosclerotic plaque debris during angioplasty procedures. Angioslide focuses on addressing the needs of various markets, including peripheral artery, lower limb artery, carotid, and coronary artery diseases.

Cardiva Medical, Inc. is a medical device company that specializes in vascular access management products designed to facilitate the body's healing process after catheterization procedures. The company offers several innovative products, including the VASCADE VCS, an extravascular and bioabsorbable femoral access closure system that promotes rapid hemostasis while reducing complications. Additionally, Cardiva Medical provides the Cardiva CATALYST, a manual compression assistance device that enhances coagulation for patients requiring temporary hemostasis. Another key product is the VASCADE MVP, which is used for multi-site venous closure during electrophysiology procedures, such as cardiac ablation. Founded in 2002 and headquartered in Santa Clara, California, Cardiva Medical serves physicians and cardiac centers throughout the United States, focusing on transforming vascular closure practices to improve patient outcomes.

FEMSelect Inc. specializes in designing and developing surgical systems and devices for pelvic floor ligament fixation, focusing on women's health. The company is known for its innovative EnPlace system, a minimally invasive and mesh-free solution for treating pelvic organ prolapse (POP). This patented technology allows for precise guidance and deployment of an anchor unit that stabilizes the pelvic floor ligament through a vaginal approach, significantly enhancing patient recovery and comfort. The procedure typically takes about 30 minutes and does not require overnight hospital stays or result in visible scarring. Founded in 2012, FEMSelect operates from its headquarters in Newark, Delaware.